Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
Conditions
Interventions
Intervention1: Oral Tofacitinib 5 mg twice daily till the end of study: Oral Tofacitinib 5 mg twice daily till the end of 12 weeks or if resolution of lesions occurs before that
Control Intervention1:
Sponsors
nil
Eligibility
Inclusion criteria
Inclusion criteria: Patients willing to participate in the study with giving written informed consent for participation Patients having moderate prurigo nodular with 20 to 100 lesions Patients having severe prurigo nodules with more than 100 lesions
Exclusion criteria
Exclusion criteria: Patients with absolute lymphocyte count less than 500 per mm3 or absolute neutrophil count less than 1000 per mm3 or haemoglobin less than 9 g per dl. Pregnant or lactating women Patients with contraindications to the use of tofacitinib like any physiologic or pathologic immunocompromised conditions like tuberculosis, HIV, organ transplant recipient or any active infections, malignancies, history of hypersensitivity, dyslipidemia, venous thromboembolism, stroke, heart failure, ischemic heart disease or any other uncontrolled or serious medical condition.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| numeric rating scale for pruritusTimepoint: week 0 week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| nodular lesion count decreaseTimepoint: week 0 to week 12;investigators global assessment scaleTimepoint: week 12;dermatology life quality indexTimepoint: week 12;patients self assessmentTimepoint: week 12;sleep scoreTimepoint: week 0 to week 12 | — |
Countries
India
Contacts
Public ContactDr Bushra Iqbal Khan
GMC Nagpur
Outcome results
None listed